Advent Access

Advent Access is a Singapore-based medical technology company focused on improving the lives of patients with end-stage renal disease. Founded in late 2015 by Peh Ruey Feng, the company was spun off from Singapore's Agency for Science, Technology and Research (A*STAR). Peh, who serves as the CEO, has an extensive background in medical device innovation, having been a founding faculty member of the Singapore-Stanford Biodesign program and an inventor on numerous patents in renal and cardiovascular technologies. His experience in Silicon Valley startups and his recognition as a top innovator underscore his drive to address critical challenges in healthcare.

The company's core mission is to reduce the cost and complications associated with hemodialysis, a life-sustaining treatment for kidney failure patients that operates within a global market valued at over $70 billion. Vascular access, the site where blood is drawn for dialysis, is a major pain point, often leading to complications, hospitalizations, and significant stress for patients. Advent Access targets this issue directly with its main product, the av-Guardian™. This device is a small, implantable "guardian guide-door" placed under the skin, above the surgically created vein (an arteriovenous fistula) used for dialysis. The av-Guardian™ is designed to guide the dialysis needle to the correct spot, engineering a stable tissue track. This approach reduces wear and tear on the vein, minimizes pain, and simplifies the needling process, which could eventually enable patients to perform the procedure themselves at home.

The business model centers on the development and commercialization of its medical devices. A significant milestone was achieved in July 2019 when Advent Access received the CE Mark for the av-Guardian™, permitting its sale in the European Economic Area. This approval followed successful clinical studies in Singapore that demonstrated the device's safety and high success rate in providing vascular access. The company has been backed by notable investors, including a S$2.6 million pre-Series A round in 2017 led by Accuron MedTech, a subsidiary of Temasek Holdings. In 2018, Advent Access strategically acquired the global manufacturing and commercialization rights for the Vwing™ Vascular Needle Guide from the U.S. firm Vital Access, expanding its portfolio to address more complex cases, such as those in obese patients. While one source indicates the company is out of business as of July 2025, this is not substantiated by other search results and may be inaccurate.

Keywords: Advent Access, medical technology, hemodialysis, end-stage renal disease, vascular access, av-Guardian, Peh Ruey Feng, medical device, dialysis solutions, kidney failure, CE Mark, Accuron MedTech, A*STAR, Singapore startup, medtech innovation, arteriovenous fistula, self-cannulation, home dialysis, Vwing, vascular needle guide, renal care, chronic disease management, Singapore-Stanford Biodesign